NASDAQ$ATEC

Alphatec Holdings Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Reported Q4 and Full Year 2020 financial results and recent corporate highlights.

Alphatec Holdings, Inc. reported a 38% increase in U.S. revenue for the fourth quarter and 30% for the full year. Revenue growth has averaged approximately 30% over the past eight quarters. The company's focus on surgeon adoption and sales footprint evolution has driven market share expansion.

  • U.S. Revenue grew by 38% in Q4 and 30% for the full year.
  • New products contributed 75% of Q4 U.S. revenue, up from 48% in Q4 2019.
  • Q4 average U.S. revenue per case increased by 13% year-over-year.
  • Strategic distribution drove 47% year-over-year revenue growth in Q4.

Headline financials

Total Revenue

$44M

Previous: $32.4M+35.9%
EPS (adj)

-$0.27

Previous: -$0.18-50.0%
Capital Expenditures

$10.3M

No prior period
Free Cash Flow

-$17M

No prior period
Net Income

-$26.8M

Previous: -$17M-57.3%
Operating Income

-$17M

Previous: -$14.5M-17.5%
Gross Profit

$31.4M

Previous: $22.2M+41.4%
Cash & Equivalents

$108M

Previous: $47.1M+128.7%
Total Assets

$261M

Previous: $170M+53.7%
Stock-Based Comp

$4.97M

No prior period

Revenue & EPS history

Alphatec · Revenue · Quarterly

$44M

Q4 2020+35.9%vs Q4 2019
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Alphatec · $104M total across 1 segment · Q3 2023

  • Surgical Revenue
    $104M

Forward guidance

The Company continues to expect total revenue for the fiscal year ended December 31, 2021, to approximate $178 million, which includes U.S. revenue of approximately $176 million.

Tailwinds

  • Total revenue for fiscal year ended December 31, 2021, is expected to be approximately $178 million.
  • U.S. revenue for fiscal year ended December 31, 2021, is expected to be approximately $176 million.
  • Revenue guidance reflects expected U.S. revenue growth of approximately 25% compared to 2020.
  • Growth driven by continued launches of novel procedures and products and growing traction of the procedures and products released in 2020.
  • Company expects to update guidance to reflect the positive impact of EOS imaging when that transaction closes, which is anticipated in second quarter 2021.

Headwinds

  • Total revenue guidance contemplates the anticipated wind-down of the Company’s international supply agreement by August 2021.
  • The Company remains subject to the potential and uncertain impact of the ongoing COVID-19 pandemic.
  • If hospitals experience a surge in COVID-19 cases and defer elective procedures to preserve capacity, the Company’s ability to achieve these financial objectives may be adversely affected.
  • Uncertainties and risks related to the proposed tender offer EOS Imaging, S.A.
  • The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

-1.5%

Avg return

Earnings day

-1.4%

Avg return

5 days after

-0.1%

Avg return

30 days after

45%

29 / 64 earnings

Positive

+44.8%

Q3 2024

Best reaction

-43.2%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.9%-27.1%-23.3%
Q4 2025+0.5%-3.3%-21.5%
Q3 2025-0.8%+17.8%+36.7%
Q1 2025+2.4%+2.2%+2.2%
Q4 2024+9.6%+6.1%-7.9%
Q3 2024+44.8%+54.2%+93.4%
Q2 2024-32.8%-33.7%-30.2%
Q1 2024-20.2%-13.3%-22.7%
Q4 2023-7.4%-11.1%-8.6%
Q3 2023+4.7%-1.5%+20.8%
Q2 2023-7.1%-10.4%-5.2%
Q1 2023+3.1%+3.8%+4.5%
Q4 2022+1.6%+7.9%+6.3%
Q3 2022-1.5%-1.4%+9.5%
Q2 2022-0.2%-3.8%-10.9%
Q1 2022-16.1%-27.7%-34.0%
Q4 2021+3.1%+3.4%+4.4%
Q3 2021-2.2%-8.2%-18.7%
Q2 2021+2.4%-5.8%-0.2%
Q1 2021-2.0%-9.1%-8.3%
Q4 2020-7.6%+4.2%-2.1%
Q3 2020+9.4%+4.7%+22.1%
Q2 2020+21.8%+5.6%+3.1%
Q1 2020-8.0%-13.9%+5.7%
Q4 2019-8.4%-20.8%-47.2%
Q3 2019+15.2%+16.1%+18.1%
Q2 2019+9.3%+8.5%+26.2%
Q1 2019+5.4%+15.8%+8.8%
Q4 2018+14.7%+16.6%+22.1%
Q3 2018-1.7%-5.6%-13.5%
Q2 2018+4.7%+15.0%+28.1%
Q1 2018-2.0%-0.9%-1.1%
Q4 2017+0.9%-5.0%+1.2%
Q3 2017-0.8%-0.6%-30.5%
Q2 2017+2.4%+2.4%+40.2%
Q1 2017+1.9%+0.0%-4.8%
Q4 2016-16.0%-27.0%-45.8%
Q3 2016-15.8%-8.0%-12.8%
Q2 2016+2.5%+0.0%-6.5%
Q1 2016-11.8%
Q4 2015-13.8%
Q3 2015+5.8%
Q2 2015-42.6%
Q1 2015+1.4%
Q4 2014+7.4%
Q3 2014-0.7%
Q2 2014+0.0%
Q1 2014+2.3%
Q4 2013+22.3%
Q3 2013-0.5%
Q2 2013-3.9%
Q1 2013-3.2%
Q4 2012+2.6%
Q3 2012-1.8%
Q2 2012-2.5%
Q1 2012-7.4%
Q4 2011-0.5%
Q3 2011-5.6%
Q2 2011-10.4%
Q1 2011+3.7%
Q4 2010+0.4%
Q3 2010-9.6%
Q2 2010-43.2%
Q1 2010+6.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro